Generic Name: human insulin
Brand Name: Entuzity KwikPen
Manufacturer: Eli Lilly Canada Inc.
Therapeutic Area: Diabetes mellitus
Indications: To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Manufacturer Requested Reimbursement Criteria1: To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Submission Type: Initial
NOC Status at Filing: Post NOC
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule C
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient/clinician input open||December 22, 2020|
|Call for patient/clinician input closed||February 22, 2021|
- Patient input submission received from Diabetes Canada
|Submission received||January 27, 2021|
|Submission accepted||February 10, 2021|
|Review initiated||February 11, 2021|
|Draft CADTH review report(s) provided to sponsor for comment||April 30, 2021|
|Deadline for sponsors comments||May 11, 2021|
|CADTH responses on draft review report(s) provided to sponsor||June 04, 2021|
|Expert committee meeting (initial)||June 16, 2021|
|Draft recommendation issued to sponsor||June 28, 2021|
June 30, 2021